CD22 Redirected Autologous T Cells for ALL

Running, not enrolling · Phase 1

Conditions studied: B Cell Leukemias, B Cell Lymphomas

In brief

This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult subjects with relapsed or refractory B cell acute lymphoblastic leukemia.

Key facts

Study ID

NCT02650414

Run by

University of Pennsylvania

People needed

41

Starts

2016-01-13

Expected to finish

2037-12-01

Last updated by the study team

2026-07-07

Who can join

Age: 1 and older, up to 29. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Active hepatitis B or active hepatitis C.
• HIV Infection.
• Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.
• Concurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary.
• CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
• Pregnant or nursing (lactating) women.
• Receipt of a prior investigational study agent within 4 weeks prior to screening visit. *Note - patients who have received anti-CD19 CART cells (e.g., CART19/CTL019) on an investigational study where cell infusion occurred greater than 4 weeks before the screening visit are NOT excluded.

Where it is running

• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.